$NTRA

Sheena Jonathan sold $2.0M of NTRA

Sheena Jonathan sold 6,000 shares of Natera, Inc. (NTRA) at $325.32 ($1.95M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Aug 15, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 2:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and post-transaction holdings by a director under a 10b5-1 plan.

02

Market read

Traders may monitor insider activity, but a 10b5-1 sale typically has limited informational content absent accompanying company news.

03

What to watch

The article provides no context on total insider holdings, sale frequency, or whether other insiders are selling/buying around the same period, limiting inference.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-14 for a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold 6,000 shares in an open-market transaction at $325.3237 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

No clear sector read-through; this is company-specific insider selling with no operational or regulatory trigger described.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with valuation or liquidity needs, which some traders may still treat as a mild bearish signal.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Sheena Jonathan

    Director who sold 6,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.